Graz

• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Study to learn about the safety of fazirsiran and if it can help people with alpha-1 antitrypsin liver disease with mild liver scarring (fib … Recruiting
  2023-504198-19-00 5 2024-04-18 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting
  2023-504973-19-01 5 2023-09-06 early-stage, intermediate-risk cervical cancer
• A study to evaluate the efficacy and safety of QMF149 (indacaterol acetate/mometasone furoate) versus Budesonide in children from 6 to less … Recruiting
  2022-501899-26-00 5 2023-09-01 Asthma
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr … Recruiting
  2024-512320-11-00 5 2023-08-09 Primary diffuse large B-cell lymphoma of the central nervous system (P
• Desflurane versus Sevoflurane versus Propofol on postoperative delirium in elderly patients Recruiting
  2023-503717-30-00 11 2023-07-19 Elderly patients undergoing moderate- to high-risk major non cardiac s
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma … Recruiting
  2022-501943-34-00 5 2023-06-27 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Recruiting
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer Recruiting
  2024-511219-78-00 5 2023-02-28 epithelial ovarian cancer
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin rece … Recruiting
  2023-504885-50-00 5 2022-11-07 Treatment of children with chronic kidney disease and proteinuria
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive

Showing 145–168 of 390 trials